Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer -- Internationally recognized clinical strategist with proven track record in translating ...

Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best undervalued stocks to buy under $50. Bristol-Myers Squibb Company ...

BofA Remains Neutral on Bristol-Myers Squibb Company (BMY), Expects Low Single-Digit Growth in the Long Term

Bristol-Myers Squibb Company (NYSE:BMY) is included in our list of the 12 deep value stocks to invest in. On November 3, 2025 ...

Bristol Myers Squibb Co. stock rises Monday, still underperforms market

This was the stock's fourth consecutive day of gains.

Bristol-Myers, Rockefeller University join hands to develop COVID-19 therapy

Drugmaker Bristol-Myers Squibb Co (BMY.N) will globally develop, make and sell a therapy being tested by New York's ...

Bristol Myers reaches $239 million settlement over psoriasis, MS drugs

Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now ...
Nasdaq

December 12th Options Now Available For Bristol Myers Squibb (BMY)

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the December 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Hosted on MSN

Bristol-Myers Squibb Reports Q3 2025 Financial Results

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Bristol-Myers Squibb ( ...
Seeking Alpha

Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare

Bristol-Myers Squibb is deeply undervalued despite a 23% YTD stock decline, offering compelling value in the healthcare sector. BMY faces significant patent expirations but is proactively mitigating ...
Seeking Alpha

The Play On Bristol-Myers Squibb

Bristol-Myers Squibb has had a recent 30% stock decline amid concerns over patent expirations for key blockbuster drugs through 2028. Despite two FY25 outlook raises and strong cash flow, BMY's ...
Insider Monkey

Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Beaten Down Stocks to Buy According to Hedge Funds. On October 10, Citi lifted the price target on the company’s stock to $48 from $47, while ...
Seeking Alpha

Bristol Myers Squibb, SystImmune report data from lung cancer trial

Bristol Myers Squibb (NYSE:BMY) and SystImmune reported data from an early-stage study testing their bispecific antibody-drug conjugate, iza-bren, as a treatment for advanced non-small cell lung ...